Core Scientific (CORZ) Liabilities and Shareholders Equity (2020 - 2026)

Core Scientific has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $5.3 billion for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 184.08% year-over-year to $5.3 billion; the TTM figure through Jun 2026 stood at $12.8 billion (up 127.39% YoY), while the FY2025 annual figure was $2.3 billion, up 59.06% from the prior year.
• Liabilities and Shareholders Equity came in at $5.3 billion for Q2 2026 at Core Scientific, up from $3.1 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $5.3 billion in Q2 2026 to a low of $664.2 million in Q2 2024.
• Average Liabilities and Shareholders Equity over 5 years is $1.6 billion, with a median of $1.4 billion recorded in 2022.
• Year-over-year, Liabilities and Shareholders Equity surged 677.6% in 2022 and slumped 71.89% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $807.7 million in 2022, then slipped by 11.83% to $712.2 million in 2023, then surged by 107.25% to $1.5 billion in 2024, then jumped by 59.06% to $2.3 billion in 2025, then jumped by 123.95% to $5.3 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $5.3 billion in Q2 2026, $3.1 billion in Q1 2026, and $2.3 billion in Q4 2025.